Company Profile

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-06-12	Tricida, Inc. Went Out of Business	CI
23-06-01	First Motion for Exclusivity Period Extension Approved For Tricida, Inc.	CI
23-05-23	Fifth Amended Liquidation Plan Approved for Tricida, Inc.	CI
23-05-22	Fifth Amended Liquidation Plan Filed by Tricida, Inc.	CI
23-05-12	Fourth Amended Liquidation Plan Filed by Tricida, Inc.	CI
23-05-08	First Motion for Exclusivity Period Extension Filed by Tricida, Inc.	CI
23-03-27	Fourth Amended Disclosure Statement Approved for Tricida, Inc.	CI
23-03-24	Fourth Amended Disclosure Statement Filed by Tricida, Inc.	CI
23-03-21	Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	CI
23-02-25	Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	CI
23-02-24	First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	CI
23-02-21	Motion for Asset Sale Approved for Tricida, Inc.	CI
23-02-21	Motion for Asset Sale Approved for Tricida, Inc.	CI

22-10-25	Needham Downgrades Tricida to Hold From Buy	MT
22-10-25	JPMorgan Downgrades Tricida to Underweight From Neutral	MT
22-10-24	Cowen Downgrades Tricida to Market Perform From Outperform, Removes $20 Price Target	MT
22-05-24	Goldman Sachs Adjusts Price Target for Tricida to $16 From $22, Keeps Buy Rating	MT
22-05-11	Goldman Sachs Adjusts Tricida Price Target to $22 From $25, Maintains Buy Rating	MT

23-03-15	Tricida : Acquisition/Asset Disposal - Form 8-K	PU
23-02-24	TRICIDA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
23-02-23	TRICIDA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23-02-17	TRICIDA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-01-27	TRICIDA, INC. : Financial Statements and Exhibits (form 8-K)	AQ

Director	Title	Age	Since
Robert Alpern BRD	Director/Board Member	75	2013-09-30
Thomas FitzGerald BRD	Director/Board Member	-	2023-01-08

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/23/22	Robert Alpern	Sell	Director	131,879	0.2369%
11/22/22	OrbiMed Advisors Private Equity	Sell	Company	10,280,947	18.4680%
11/22/22	OrbiMed Advisors Private Equity	Sell	Company	10,280,947	18.4680%

Tricida, Inc. Stock

Stocks

TCDA

US89610F1012

Biotechnology & Medical Research

Latest news : Tricida, Inc.

Analysts' recommendations: Tricida, Inc.

Press Releases: Tricida, Inc.

Quotes and Performance

Managers and Directors: Tricida, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRICIDA, INC.	-99.90%	-99.92%	-	-	580
LONZA GROUP AG	-1.60%	+0.86%	+3.70%	+14.41%	49.54B
REVOLUTION MEDICINES, INC.	-0.14%	+4.03%	+482.13%	+584.43%	44.06B
BEONE MEDICINES AG	-0.06%	+9.62%	+24.63%	+81.63%	40.85B
IQVIA HOLDINGS INC.	-0.87%	+2.40%	+30.01%	+9.95%	40.14B
CELLTRION, INC.	-4.04%	+6.15%	+23.03%	+48.00%	34.17B
MEDPACE HOLDINGS, INC.	-1.41%	+1.57%	+29.98%	+123.68%	16.9B
ASCENDIS PHARMA A/S	+0.35%	+4.61%	-	-	16.78B
EUROFINS SCIENTIFIC SE	-0.43%	-0.11%	+4.22%	+20.83%	14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.84%	+9.07%	+86.17%	+32.60%	13.46B
Average	-10.73%	+4.74%	+85.48%	+114.44%	29.99B
Weighted average by Cap.	-1.01%	+5.04%	+103.30%	+136.92%